Great discussion about drugs that are toxic. Before dumping these drugs, what can be done? 1. Maybe it’s not toxic. Consensus was that imatinib would be toxic because it would not differentiate normal vs bcr-abl kinase—wrong

Just saw advice on New Year’s resolutions to 1) live and 2) enjoy living and I think that’s about right - although I might add 3) do as much good in the world as you are capable of.

Tissue-agnostic targeted treatment based on molecular profile of each individual patient, this is what we do CureMatch with the lab NGS from any lab ( Guardant Health Tempus Caris Life Sciences Labcorp) as our input. We can also match patients for #oncology trials. Novartis Pfizer Inc.

We determine “molecular eligibility” of a #patient to #clinicaltrials by evaluating NGS profiles of patients and matching them with clinical trials that have highly ranked drugs or combinations for each patient’s cancer.

Well said by our CureMatch cofounder, Razelle Kurzrock, MD Why we do what we do. #precisionmedicine #cancertherapy #clinicaltrials #BreastCancer #NGS

From a senior executive of one of the large #NGS labs: CureMatch is like having a tumor board in your pocket!  #ArtificialInteligence #cancer #precisionmedicine #clinicaltrial #Oncology #cancertreatment

Webinar moderated by Director at Sheba Medical Center on CureMatch Razelle Kurzrock, MD discussed how we assist in personalized treatment, match molecular markers to enable tailored combos to address as many biomarkers as possible w/each patient’s cancer: lnkd.in/dY-ZSv_G

Congratulations to our CureMatch founder, Razelle Kurzrock, MD and all of you #cancer warriors!

Here is a great quote from our co-founder Razelle Kurzrock, MD highlighting the #CureMatch value add: “The average tumor has five genomic alterations, and if there are about 700 cancer genes, that means greater than one trillion patterns.“ #artificialntelligence #precisiononcology

Cancer care should be as unique as the patients we serve. Razelle Kurzrock, MD is leading the charge in precision medicine, ensuring patients get treatments tailored to their tumor profiles. mcw-cancercenter.cmail19.com/t/r-e-thjdlyik… #WomensHistoryMonth #WomenInScience #PrecisionMedicine

From our CureMatch founder Razelle Kurzrock, MD

Our CureMatch founder Razelle Kurzrock, MD’s paper. The average tumor has 5 genomic alterations, and if there are about 700 cancer genes, that means greater than one trillion patterns. This is beyond human cognition, and where #AI becomes a critical part of #precisiononcology

Great paper by our CureMatch cofounder Razelle Kurzrock, MD & colleagues.

From our CureMatch cofounder, Razelle Kurzrock, MD

Razelle Kurzrock, MD Hats off to all including our cofounder Razelle Kurzrock, MD , Vivek Subbiah, MD on this! At CureMatch our input is the NGS output, and we can then assist on the patient matching and stratification of the #clinicaltrial

This is where a @curematch report can be critical to account for multiple tumor pathways, some of which could lead to hyper-progression if not factored into treatment selection.

Razelle Kurzrock, MD This is where a @curematch report can be critical to account for multiple tumor pathways, some of which could lead to hyper-progression if not factored into treatment selection.